The world has woken up to a new era, with Donald Trump elected as US president – a huge victory for a political outsider and the 'silent majority' who felt sidelined by the status quo.

A problem very rarely spoken about is the treatments that are promising, but are not developed further. Ben Hargreaves finds that these drug candidates are often left in limbo and never see the ...

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI). The study used ...

During election cycles, much is made of policy positions on the economy, immigration, foreign affairs, etc. However, rarely is attention paid to the policy of science. With every vote, Americans ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility. The new plant ...

Credit COVID-19, the evolution of technology, changing physician workflows, or some combination of the three. But whatever the reason, digital technology has rapidly shifted the landscape of ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Indivior has secured a $111 million supply contract from the US federal government for its intranasal therapy for treating opioid overdose, in a further boost to the UK company’s fortunes.

The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident. Ben Hargreaves examines how the drugs have been a major ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...

There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. Ben ...